Impact of human serum albumin on oritavancin in vitro activity against enterococci.
Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycin-resistant enterococci. The impact of human serum albumin (HSA) on oritavancin activity against enterococci was compared to those of vancomycin, daptomycin, teicoplanin, and linezolid in vitro using MIC and time-kill methods. Oritavancin MICs increased between 0- and 8-fold in the presence of HSA. In time-kill assays with HSA, oritavancin retained activity, killing or inhibiting enterococci more rapidly than did comparators when peak concentrations were simulated.
Targanta Therapeutics Incorporated, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1.
Geoffrey A
GA
McKay
Sylvain
S
Beaulieu
Ingrid
I
Sarmiento
Francis F
FF
Arhin
Thomas R
TR
Parr
Gregory
G
Moeck
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D016983:Enterococcus / Q000187:drug effects*; D006020:Glycopeptides / Q000378:metabolism / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D012709:Serum Albumin; C100708:oritavancin; D014640:Vancomycin